

## S 4037

### Pharmaceutical Research Transparency Act of 2022

**Congress:** 117 (2021–2023, Ended)

**Chamber:** Senate

**Policy Area:** Health

**Introduced:** Apr 7, 2022

**Current Status:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

**Latest Action:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Apr 7, 2022)

**Official Text:** <https://www.congress.gov/bill/117th-congress/senate-bill/4037>

## Sponsor

**Name:** Sen. Stabenow, Debbie [D-MI]

**Party:** Democratic • **State:** MI • **Chamber:** Senate

## Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Smith, Tina [D-MN]	D · MN		Apr 7, 2022
Sen. Klobuchar, Amy [D-MN]	D · MN		Nov 14, 2022

## Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Apr 7, 2022

## Subjects & Policy Tags

### Policy Area:

Health

## Related Bills

Bill	Relationship	Last Action
117 HR 7474	Identical bill	Apr 8, 2022: Referred to the Subcommittee on Health.
117 HR 4747	Identical bill	Aug 4, 2021: Referred to the Subcommittee on Asia, the Pacific, Central Asia and Nonproliferation.

## **Pharmaceutical Research Transparency Act of 2022**

This bill requires the disclosure of costs associated with clinical trials and pharmaceutical research and development.

Specifically, the National Institutes of Health must create a publicly available repository of cost data from certain clinical trials that test the efficacy of drugs, biological products, and devices in human subjects. For each applicable trial, the registry must, among other information, include the total and per patient cost of the trial, as well as costs for personnel, health care services, and other categories of expenditures. Information must be added to the registry within one year of the trial's completion.

The bill also requires drug manufacturers to include their research and development expenditures for drugs and biological products in annual disclosures made to the Securities and Exchange Commission.

### **Actions Timeline**

---

- **Apr 7, 2022:** Introduced in Senate
- **Apr 7, 2022:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.